The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome

Alison W Rebman, Kathleen T Bechtold, Ting Yang, Erica A Mihm, Mark J Soloski, Cheryl B Novak, John N Aucott, Alison W Rebman, Kathleen T Bechtold, Ting Yang, Erica A Mihm, Mark J Soloski, Cheryl B Novak, John N Aucott

Abstract

Background: The increased incidence and geographic expansion of Lyme disease has made it the most common vector-borne infection in North America. Posttreatment Lyme disease syndrome (PTLDS) represents a subset of patients who remain ill following standard antibiotic therapy for Lyme disease. The spectrum of symptoms and their impact on quality of life remain largely unexplored among patients with well-documented PTLDS.

Objective: To characterize a case series of patients with well-documented PTLDS compared to a sample of healthy controls.

Methods: Sixty-one participants met the proposed case definition for PTLDS. Twenty-six healthy controls had neither a clinical history of Lyme disease nor current antibodies to Borrelia burgdorferi. Participants with PTLDS and controls were evaluated by physical exam, clinical laboratory testing, standardized questionnaires, and a 36-item current symptom list.

Results: Compared to controls, participants with PTLDS reported significantly greater fatigue, pain, sleep disturbance, and depression (Fatigue Severity Scale: 50.0 ± 10.6 vs. 19.8 ± 8.6; Short-Form McGill Pain Questionnaire: 13.7 ± 8.3 vs. 0.8 ± 1.9; Pittsburgh Sleep Quality Index: 10.1 ± 4.7 vs. 4.1 ± 2.1; Beck Depression Inventory-II: 15.1 ± 7.7 vs. 2.2 ± 3.2; p < 0.001 for each), and significantly lower quality of life (SF-36 Physical Component Score: 33.9 ± 9.7 vs. 55.1 ± 6.2; Mental Component Score: 42.9 ± 10.1 vs. 54.2 ± 5.4; p < 0.001 for each). Nineteen non-PTLDS-defining symptoms were found to be significantly more severe among participants with PTLDS than controls, including sleep difficultly and visual complaints. Initial delayed or misdiagnosis was characterized in 59.0% of participants with PTLDS, and 32.2% had abnormal vibratory sense.

Conclusion: Although physical exam and clinical laboratory tests showed few objective abnormalities, standardized symptom questionnaires revealed that patients with PTLDS are highly and clinically significantly symptomatic, with poor health-related quality of life. PTLDS patients exhibited levels of fatigue, musculoskeletal pain, sleep disturbance, and depression which were both clinically relevant and statistically significantly higher than controls. Our study shows that PTLDS can be successfully identified using a systematic approach to diagnosis and symptom measurement. As the prevalence of PTLDS continues to rise, there will be an increased need for physician education to more effectively identify and manage PTLDS as part of integrated patient care.

Keywords: Lyme disease; case series; posttreatment Lyme disease syndrome; quality of life; signs and symptoms.

Figures

Figure 1
Figure 1
Participants with posttreatment Lyme disease syndrome (PTLDS) were compared to controls on the following: (A) Fatigue Severity Scale, (B) the Short-Form McGill Pain Index, (C) Pittsburgh Sleep Quality Index, (D) the Beck Depression Inventory-II, and the SF-36 (E) Physical and (F) Mental norm-based scores. The mean and 1 SD are shown by the solid lines. Clinically relevant cutoffs for each measure are shown by the dotted line.
Figure 2
Figure 2
Participants with posttreatment Lyme disease syndrome (PTLDS) and controls were asked about presence and severity of 36 signs/symptoms over the past 2 weeks. Displayed are the 25 signs/symptoms with a statistically significant difference in severity by group (p < 0.05), ordered by frequency within the PTLDS group. The nine signs/symptoms with a statistically significant difference at the p < 0.001 level are indicated with an asterisk.

References

    1. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease-a tick-borne spirochetosis? Science (1982) 216(4552):1317–9.10.1126/science.7043737
    1. Adams DA, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, et al. Summary of notifiable diseases – United States, 2012. MMWR Morb Mortal Wkly Rep (2014) 61(53):1–121.
    1. Centers for Disease Control and Prevention. Lyme Disease Data and Statistics (2017). Available from:
    1. Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, et al. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis (2014) 59(5):676–81.10.1093/cid/ciu397
    1. Steere AC. Lyme disease. N Engl J Med (2001) 345(2):115–25.10.1056/NEJM200107123450207
    1. Nadelman RB, Nowakowski J, Forseter G, Goldberg NS, Bittker S, Cooper D, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med (1996) 100(5):502–8.10.1016/S0002-9343(95)99915-9
    1. Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere LF, Holmgren D, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med (2003) 115(2):91–6.10.1016/S0002-9343(03)00308-5
    1. Aucott J, Morrison C, Munoz B, Rowe PC, Schwarzwalder A, West SK. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis (2009) 9:79.10.1186/1471-2334-9-79
    1. Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, et al. Lyme borreliosis. Nat Rev Dis Primers (2016) 2:16090.10.1038/nrdp.2016.90
    1. Marques A. Chronic Lyme disease: a review. Infect Dis Clin North Am (2008) 22(2):341–60,vii–viii.10.1016/j.idc.2007.12.011
    1. Feder HM, Jr, Johnson BJ, O’Connell S, Shapiro ED, Steere AC, Wormser GP, et al. A critical appraisal of “chronic Lyme disease”. N Engl J Med (2007) 357(14):1422–30.10.1056/NEJMra072023
    1. Strle K, Stupica D, Drouin EE, Steere AC, Strle F. Elevated levels of IL-23 in a subset of patients with post-Lyme disease symptoms following erythema migrans. Clin Infect Dis (2014) 58(3):372–80.10.1093/cid/cit735
    1. Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, et al. CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol (2016) 23(9):757–66.10.1128/CVI.00071-16
    1. Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, et al. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One (2012) 7(1):e29914.10.1371/journal.pone.0029914
    1. Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest (2012) 122(7):2652–60.10.1172/JCI58813
    1. Asch ES, Bujak DI, Weiss M, Peterson MG, Weinstein A. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol (1994) 21(3):454–61.
    1. Shadick NA, Phillips CB, Logigian EL, Steere AC, Kaplan RF, Berardi VP, et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med (1994) 121(8):560–7.10.7326/0003-4819-121-8-199410150-00002
    1. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, DeSanna ET, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med (1983) 99(1):22–6.10.7326/0003-4819-99-1-76
    1. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med (1996) 124(9):785–91.10.7326/0003-4819-124-9-199605010-00002
    1. Jowett N, Gaudin RA, Banks CA, Hadlock TA. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope (2017) 127(6):1451–8.10.1002/lary.26273
    1. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 43(9):1089–134.10.1086/508667
    1. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis (2001) 33(6):780–5.10.1086/322669
    1. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med (2001) 345(2):85–92.10.1056/NEJM200107123450202
    1. Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis (2015) 61(12):1800–6.10.1093/cid/civ735
    1. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med (2002) 136(6):421–8.10.7326/0003-4819-136-6-200203190-00005
    1. Centers for Disease Control and Prevention. Lyme Disease (Borrelia burgdorferi) 2011 Case Definition (2011). Available from:
    1. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep (1995) 44(31):590–1.
    1. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA (1984) 252(14):1905–7.10.1001/jama.252.14.1905
    1. Martina IS, van Koningsveld R, Schmitz PI, van der Meché FG, van Doorn PA. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry (1998) 65(5):743–7.10.1136/jnnp.65.5.743
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 46(10):1121–3.10.1001/archneur.1989.00520460115022
    1. Melzack R. The short-form McGill Pain Questionnaire. Pain (1987) 30(2):191–7.10.1016/0304-3959(87)91074-8
    1. Duschek S, Mannhart T, Winkelmann A, Merzoug K, Werner NS, Schuepbach D, et al. Cerebral blood flow dynamics during pain processing in patients with fibromyalgia syndrome. Psychosom Med (2012) 74(8):802–9.10.1097/PSY.0b013e3182676d08
    1. Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res (1989) 28(2):193–213.10.1016/0165-1781(89)90047-4
    1. Beck A, Steer R, Brown G. Beck Depression Inventory – Second Edition Manual. San Antonio: The Psychological Corporation; (1996).
    1. Ware JE, Kosinski M, Dewey JE. How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI: Quality Metric Inc. (2000).
    1. Agarwal AK, Garg R, Ritch A, Sarkar P. Postural orthostatic tachycardia syndrome. Postgrad Med J (2007) 83(981):478–80.10.1136/pgmj.2006.055046
    1. Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Postural orthostatic tachycardia syndrome following Lyme disease. Cardiol J (2011) 18(1):63–6.
    1. Chandra AM, Keilp JG, Fallon BA. Correlates of perceived health-related quality of life in post-treatment Lyme encephalopathy. Psychosomatics (2013) 54(6):552–9.10.1016/j.psym.2013.04.003
    1. Lobraico J, Butler A, Petrini J, Ahmadi R. New insights into stages of Lyme disease symptoms from a novel hospital-based registry. J Prim Care Community Health (2014) 5(4):284–7.10.1177/2150131914540693
    1. Greenberg HE, Ney G, Scharf SM, Ravdin L, Hilton E. Sleep quality in Lyme disease. Sleep (1995) 18(10):912–6.
    1. Mikkilä HO, Seppälä IJ, Viljanen MK, Peltomaa MP, Karma A. The expanding clinical spectrum of ocular Lyme borreliosis. Ophthalmology (2000) 107(3):581–7.10.1016/S0161-6420(99)00128-1
    1. Matta NS, Singman EL, McCarus C. Lyme disease and convergence insufficiency: is it a near fit? Am Orthopt J (2006) 56:147–50.10.3368/aoj.56.1.147
    1. Weinstein A, Britchkov M. Lyme arthritis and post-Lyme disease syndrome. Curr Opin Rheumatol (2002) 14(4):383–7.10.1097/00002281-200207000-00008
    1. Berende A, ter Hofstede HJ, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med (2016) 374(13):1209–20.10.1056/NEJMoa1505425
    1. Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP. Response to meta-analysis of Lyme borreliosis symptoms. Int J Epidemiol (2005) 34(6):1437–9.10.1093/ije/dyi241
    1. Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. Am J Med (2010) 123(1):79–86.10.1016/j.amjmed.2009.05.011
    1. Wormser GP, Weitzner E, McKenna D, Nadelman RB, Scavarda C, Molla I, et al. Long-term assessment of health-related quality of life in patients with culture-confirmed early Lyme disease. Clin Infect Dis (2015) 61(2):244–7.10.1093/cid/civ277
    1. Cairns V. Post-Lyme disease symptoms. Am J Med (2010) 123(8):e21.10.1016/j.amjmed.2010.01.029
    1. Wills AB, Spaulding AB, Adjemian J, Prevots DR, Turk SP, Williams C, et al. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis (2016) 62(12):1546–51.10.1093/cid/ciw189

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere